In last decades there has been an important improvement in survival from breast cancer, but most of that benefit has occurred in the estrogen receptor (+) and human epidermal growth factor receptor (HER)-2(+) subgroups.Triplenegative breast cancer, which is a tumor that is negative for ER, progesterone receptor, and HER-2, represent the less important group according to their frequent but due to its poor prognosis it produces a high percentage of metastatic cases and breast cancer deaths.While chemotherapy is effective in triple-negative disease, research continues to find better target therapies.These patients benefit from chemotherapy, but better treatment options are needed (less toxic treatment, reduce the risk of disease progression, and more targeted).Antiangiogenic agents such as bevacizumab have demonstrated efficacy.More recently treatments such as poly (ADP-ribose) polymerase inhibitors, and therapies that target cancer stem cells could also have an important impact in these patients.This abstract will focus on the molecular stratification of triple-negative breast cancers and the therapeutic implications of these classifications.